Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Feasibility of the LUM Imaging System for Peritoneal Surface Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03834272
Recruitment Status : Recruiting
First Posted : February 7, 2019
Last Update Posted : May 13, 2019
Sponsor:
Information provided by (Responsible Party):
Lumicell, Inc.

Brief Summary:
This single-site, feasibility study to assess the initial safety and efficacy of the LUM Imaging System for in vivo imaging of metastases to the peritoneum from primary gastrointestinal cancer, ovarian cancer and mesothelioma. This feasibility study consists of two parts: (a) a dose escalation phase to select the optimal dose followed by (b) enrollment of additional patients to develop the tumor detection algorithm.

Condition or disease Intervention/treatment Phase
Peritoneal Metastases Combination Product: LUM Imaging System Not Applicable

Detailed Description:

This study is being conducted to see if LUM015 can be safely given to human patients before surgery at a dose that allows the removed tumor tissue to be identified when imaged by the LUM imaging device.

The first 6 subjects will receive an intravenous injection of LUM015 intraoperatively with a dose of either 1.0 mg/kg or 1.5 mg/kg. The first three subjects will receive a dose of 1.0 mg/kg and if there are no adverse events the next three subject will receive the increased dose of 1.5 mg/kg. LUM015 will be given through a vein in the arm.

When the final dose of LUM015 has been determined, 12 additional subjects will be given that final dose.

The sequence of events during the surgical procedure will vary based on the standard of care used by the surgeon. Study treatment ends when the surgery is completed. All patients will continue their enrollment in the study until their first follow-up visit and they will continue to be followed until the medical team determines no further surgical intervention is required. Patients with adverse events that are determined to be possibly related to the LUM Imaging System will be followed until resolution or stabilization of the adverse event.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 18 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: Dose Escalation
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Feasibility of the LUM Imaging System for Detection of Peritoneal Surface Malignancies
Actual Study Start Date : March 18, 2019
Estimated Primary Completion Date : November 1, 2019
Estimated Study Completion Date : December 1, 2019


Arm Intervention/treatment
Experimental: 1st Tier Dose Level- LUM Imaging System
3 patients will be administered a single dose of LUM015 at 1.0 mg/kg.Imaging with the LUM imaging device will be performed in vivo and ex vivo on surgical tissue.
Combination Product: LUM Imaging System
Patients will be injected with one of 2 study doses of LUM015 and tissue will be imaged in vivo and ex vivo with the LUM imaging device.

Experimental: 2nd Tier Dose Level- LUM Imaging System
3 patients will be administered a single dose of LUM015 at 1.5 mg/kg.Imaging with the LUM imaging device will be performed in vivo and ex vivo on surgical tissue.
Combination Product: LUM Imaging System
Patients will be injected with one of 2 study doses of LUM015 and tissue will be imaged in vivo and ex vivo with the LUM imaging device.

Experimental: 3rd Tier Dose Level- LUM Imaging System
12 patients will receive LUM015 at the dose and timepoint selected based on the analysis of the data
Combination Product: LUM Imaging System
Patients will be injected with one of 2 study doses of LUM015 and tissue will be imaged in vivo and ex vivo with the LUM imaging device.




Primary Outcome Measures :
  1. Initial efficacy of LUM015 in labeling peritoneal surface malignancies by molecular imaging by comparing imaging results with pathology [ Time Frame: 1 Day ]
    Correlate the fluorescence levels in tumor tissue imaging to the dose of LUM015 injected.


Secondary Outcome Measures :
  1. Number of patients with reported adverse events [ Time Frame: up to 5 weeks post surgery ]
    Reported adverse events will be assessed and aggregated according to event type, relation to device or drug, and severity.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects must have histologically or cytologically confirmed metastases to the peritoneum from gastrointestinal cancer, ovarian cancer or mesothelioma prior to surgery.
  • Subjects must be scheduled for surgical resection.
  • Age of 18 years or older.
  • Subjects must be able and willing to follow study procedures and instructions.
  • Subjects must have received and signed an informed consent form.
  • Subjects must be otherwise healthy except for the diagnosis of cancer, as per the criteria listed below.
  • Subjects must have normal organ and marrow function as defined as:

    • Leukocytes > 3,000/mcL
    • Absolute neutrophil count > 1,500/mcL
    • Platelets > 100,000/mcL
    • total bilirubin within normal institutional limits
    • AST (SGOT)/ALT (SGPT) < 2.5 X institutional upper limit of normal
    • Creatinine within normal institutional limits or creatinine clearance > 60 mL/min/1.73 m2 for subjects with creatinine levels above institutional normal.
  • Subjects with ECOG performance status of 0 or 1.

Exclusion Criteria:

  • Subjects who are pregnant or nursing at the time of diagnosis.
  • Subjects who are sexually active and not willing/able to use medically acceptable forms of contraception (hormonal or barrier method of birth control, abstinence) upon entering the study and for 60 days after injection of LUM015.
  • Subjects who have taken an investigational drug within 30 days of enrollment.
  • Subjects who have not recovered from adverse events due to other pharmaceutical or diagnostic agents.
  • Subjects with uncontrolled hypertension defined as persistent systolic blood pressure > 180 mm Hg, or diastolic blood pressure > 100 mm Hg; those subjects with known HTN should be under these values while under pharmaceutical therapy.
  • History of allergic reaction attributed to drugs containing polyethylene glycol (PEG).
  • History of allergic reaction to any oral or intravenous contrast agents.
  • Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, COPD or asthma requiring hospitalization within the past 12 months, or psychiatric illness/social situations that would limit compliance with study requirements.
  • HIV-positive individuals on combination antiretroviral therapy are ineligible.
  • Any subject for whom the investigator feels participation is not in the best interest of the subject.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03834272


Contacts
Layout table for location contacts
Contact: Jorge Ferrer, Ph.D. 617-4041040 jmferrer@lumicell.com
Contact: Kate Smith, MPH, CCRP 7815918378 ext 7815918378 kate@lumicell.com

Locations
Layout table for location information
United States, Massachusetts
Massachusetts General Hospital Recruiting
Boston, Massachusetts, United States, 02114
Contact: James C Cusack, MD         
Sponsors and Collaborators
Lumicell, Inc.
Investigators
Layout table for investigator information
Principal Investigator: James C Cusack, MD Massachusetts General Hospital

Layout table for additonal information
Responsible Party: Lumicell, Inc.
ClinicalTrials.gov Identifier: NCT03834272     History of Changes
Other Study ID Numbers: CLP-00010
First Posted: February 7, 2019    Key Record Dates
Last Update Posted: May 13, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Pediatric Postmarket Surveillance of a Device Product: No
Keywords provided by Lumicell, Inc.:
Gastrointestinal Cancer
Ovarian Cancer
Mesothelioma
Peritoneal surface malignancies
Additional relevant MeSH terms:
Layout table for MeSH terms
Peritoneal Neoplasms
Neoplasms
Abdominal Neoplasms
Neoplasms by Site
Digestive System Neoplasms
Digestive System Diseases
Peritoneal Diseases